Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The Democratic Republic of Congo is currently facing its 17th outbreak of the Ebola virus. While scientists have identified the outbreak as being caused by the rare Bundibugyo strain, a major concern is that there is currently no approved treatment or vaccine specifically targeting it.

Although highly effective vaccines such as ERVEBO exist, they are designed specifically for the Zaire strain of Ebola and do not protect against other strains like Sudan or Bundibugyo.

Now, a team of scientists at the Université de Montréal (UdeM) in Canada has identified a new family of natural molecules with strong antiviral activity, particularly against the Ebola virus.

Previously, in 2016 and again in 2020, researchers at the university’s Montreal Clinical Research Institute (IRCM) demonstrated that a plant extract rich in isoquercitrin — a flavonoid found in many plants — showed strong antiviral activity in laboratory studies.

However, the exact source of the effect remained unclear.

What Were The Plant Molecules?

Researchers, including scientists from the University of Chicago, used advanced analytical methods and a rigorous bioassay-guided approach to determine that the antiviral activity did not originate from isoquercitrin itself, but rather from two previously unknown triterpenoid compounds.

Though present at only 0.4 per cent of the analyzed extract, these newly identified molecules — named dicitriosides — proved to be up to 25 times more active than the original extract against the Ebola virus under experimental conditions.

The compounds were also found to be effective against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Researchers noted that the molecules demonstrated antiviral efficacy at pharmacologically achievable concentrations.

“This discovery illustrates how compounds present in vanishingly small amounts in nature can have major therapeutic potential,” said Majambu Mbikay from the IRCM. “It also underscores the importance of carefully examining the true composition of natural products used in biomedical research.”

The scientists noted in the study that even though the findings are "still at the preclinical stage, it opens promising avenues for the discovery of new broad-spectrum antivirals derived from natural products”.

“No one knows when the next pandemic will occur, but one thing is certain: we must be prepared,” said Michel Chrétien, medical professor at UdeM. “These results demonstrate the importance of long-term fundamental research and international collaboration in anticipating the public-health challenges of the future.”

The Ebola Outbreak

On May 17, the World Health Organization declared it a "public health emergency of international concern." The outbreak has also spread to Uganda.

According to the Africa CDC, the outbreak is caused by a rare strain of the Bundibugyo virus, for which there is no vaccine available currently.

Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past. It is different from other known ebolaviruses such as the Zaire ebolavirus and the Sudan ebolavirus.

As per the US CDC, as of May 17, there are reports of 10 confirmed cases and 336 suspected cases, including 88 deaths, in DRC.

Uganda has reported 2 confirmed cases, including 1 death, among people who travelled from DRC. No further spread has been reported. These numbers are likely to increase as the outbreak evolves.

After Eric Dane, another Grey’s Anatomy star, Russell Andrews has revealed that he has been diagnosed with amyotrophic lateral sclerosis (ALS).

The 64-year-old actor shared that he was diagnosed with the fatal disease in 2025, CNN reported.

“I am a person living with ALS,” said Andrews, known for his roles in Straight Outta Compton and Better Call Saul, alongside his fiancée, Erica Tazel.

“I was diagnosed in the late fall of last year,” he added.

ALS currently has no cure, and people diagnosed with the disease typically live three to five years after diagnosis, according to the Muscular Dystrophy Association.

However, some patients may survive for decades, like in the case of Stephen Hawking, who survived almost 40 years with a disease that usually kills people 14 months after diagnosis. Diagnosed at the age of 21, the noted astrophysicist and cosmologist lived until the age of 76.

Andrews’ co-star Eric Dane, who died earlier this year in February at the age of 53, also suffered from ALS. He died around 10 months after publicly revealing his ALS diagnosis.

Russell Andrews's Early Symptoms Of ALS

Andrews shared that his initial symptoms included occasional “twitches,” which he first believed were caused by “pinched nerves” in his neck.

Soon after, “I was not able to do things that I normally do,” he said, adding, “I was dropping cups and glasses at night. It felt like things were running up and down my arm at different times, and it was the nerves.”

Andrews also revealed that he lost health insurance during the industry shutdown caused by the strikes, delaying his diagnosis because he was unable to undergo medical evaluations.

Once he regained insurance coverage, doctors quickly referred him to a neurologist, eventually leading to the ALS diagnosis. “Within 15 minutes, the primary care physician said she would like me to see a neurologist,” Andrews said.

What Is ALS?

Read More: Ebola Bundibugyo Strain: All You Should Know About The Rare Virus

Also known as Lou Gehrig's disease, ALS targets motor neurons, nerve cells in the brain and spinal cord responsible for voluntary muscle movement. When these neurons degenerate and die, the brain can no longer communicate with muscles, leading to muscle weakness, paralysis, and eventually respiratory failure.

Most individuals with ALS retain their cognitive function, but lose the ability to walk, speak, eat, and breathe without assistance. The disease progresses over time, with most patients surviving between two and five years following diagnosis.

ALS presents in unique ways from person to person. It can begin in the limbs (limb-onset) or in muscles related to speaking and swallowing (bulbar-onset). While no cure currently exists, treatment advancements have offered hope for improved quality of life and extended survival.

ALS can affect anyone, though it is most commonly diagnosed between the ages of 40 and 70. According to the CDC, around 5,000 new cases are diagnosed annually in the United States, with about 30,000 people living with the disease at any given time.

Key Symptoms Of ALS

Symptoms of ALS can vary widely but often begin with muscle weakness, cramps, twitching, or difficulty with speech or swallowing. As the disease progresses, individuals may experience:

• Spasticity and exaggerated reflexes
• Muscle atrophy, particularly in the hands and legs
• Bulbar symptoms like difficulty speaking (dysarthria) or swallowing (dysphagia)
• Emotional lability (pseudobulbar affect)
• Breathing difficulties

What Leads To ALS?

Though the exact cause of ALS remains unknown, genetic factors play a key role in some cases. Mutations in genes such as SOD1, C9orf72, FUS, and TARDBP are linked to the disease. Environmental triggers, like toxin exposure, viral infections, and intense physical activity, are also being studied.

ALS is diagnosed by ruling out other conditions through clinical evaluation, EMG tests, genetic screening, and imaging such as MRI. Early diagnosis is essential to access therapies and plan care.

There is no cure for ALS yet, but treatments like riluzole, edaravone, and tofersen (for those with SOD1 mutations) can slow progression.

Promising research areas include gene therapy, RNA-targeted treatments, biomarkers like Neurofilament Light Chain, and artificial intelligence for diagnosis and personalized care.

The 17th outbreak of Ebola virus in the Democratic Republic of Congo has been identified as the rare Bundibugyo strain.

Bundibugyo virus disease is a rare and deadly illness that has caused outbreaks in several African countries in the past. It is different from other known ebolaviruses such as the Zaire ebolavirus and the Sudan ebolavirus.

Also Read: Ebola Virus: 6 US Nationals Likely Exposed In Congo; How The Infection Spreads And Turns Deadly

Bundibugyo virus was first identified during an outbreak in 2007 in Uganda, which resulted in 131 cases and 42 deaths.

Another Bundibugyo outbreak was reported in 2012, killing 50 per cent of the people infected in Uganda and 34 per cent in DR Congo.

As per the US CDC, as of May 17, there are reports of 10 confirmed cases and 336 suspected cases, including 88 deaths, in DRC.

Uganda has reported 2 confirmed cases, including 1 death, among people who travelled from DRC. No further spread has been reported. These numbers are subject to change as the outbreak evolves.

How Does Ebola Bundibugyo Spread?

Also read: WHO Calls Ebola Outbreak In DR Congo And Uganda An International Public Health Emergency

The Bundibugyo virus spreads through contact with the blood or bodily fluids of a person infected with or who has died from the rare Ebola strain.

It can also spread through contact with contaminated objects such as clothing, bedding, needles, and medical equipment, or through contact with infected animals such as bats and nonhuman primates.

Historically, Bundibugyo virus outbreaks have recorded fatality rates ranging from 25 per cent to 50 per cent.

Symptoms To Watch For

Symptoms of Bundibugyo virus disease are similar to other forms of Ebola and include:

• Fever
• Headache
• Muscle pain
• Weakness
• Diarrhea
• Vomiting
• Stomach pain
• Unexplained bleeding or bruising, usually in later stages of illness

The WHO has described the current outbreak as “extraordinary” because there are no approved Bundibugyo virus-specific therapeutics or vaccines, unlike the Ebola-Zaire strain. Most of the country’s previous outbreaks were caused by the Zaire strain.

Prof Trudie Lang from the University of Oxford also described dealing with Bundibugyo as “one of the most significant concerns” in the current outbreak, the BBC reported.

Symptoms are believed to appear between two and 21 days after infection.

With no approved drugs specifically targeting the Bundibugyo virus, treatment currently depends on supportive care, including managing pain, treating secondary infections, maintaining fluids, and ensuring adequate nutrition. Early medical care improves survival chances.

CDC Issues Travel Guidelines

The CDC advised people traveling to Uganda and the DR Congo to follow routine precautions. These include:

• Consider travel insurance, including medical evacuation coverage.
• Avoid contact with people showing symptoms such as fever, muscle pain, or rash.
• Avoid contact with blood, bodily fluids, or contaminated objects.
• Avoid contact with bats, forest antelopes, and nonhuman primates such as monkeys, chimpanzees, and gorillas.
• Avoid entering caves or mines where bats may live.

Travellers should monitor themselves for symptoms while in outbreak areas and for 21 days after leaving. If symptoms develop:

• Isolate immediately
• Do not travel
• Contact local health authorities or a healthcare facility before visiting in person